FDA Approves Revolutionary Pancreatic Cancer Drug Boosting Revolution Medicines' Valuation

מאת גלי וינרב

דווח לראשונה בNow 14 · אוג׳ 26, 2026

מה קרה

The FDA approved Rasonque, a new drug by Revolution Medicines, for metastatic pancreatic cancer, doubling patient survival and boosting the company’s valuation to $46 billion. The drug uniquely targets the RAS protein and showed unprecedented clinical results, leading to early approval. Revolution Medicines is exploring broader uses and faces competition from major pharma firms developing similar therapies.

• 01FDA approves Rasonque for metastatic pancreatic cancer, doubling patient survival to 13.2 months.
• 02Revolution Medicines’ stock surged 477% in a year, valuing the company at $46 billion.
• 03Rasonque targets the RAS protein, a key driver in 90%-95% of pancreatic cancers.
• 04The drug was approved based on a 500-patient trial with fewer side effects than chemotherapy.
• 05Merck’s $28-$32 billion acquisition attempt of Revolution Medicines failed over pricing.
• 06Other pharma giants and Israeli firms are developing RAS-targeting cancer therapies.

התקציר תורגם וסוכם מהמקורות למטה על ידי baba. לקריאה המלאה פתחו כל מקור.

סיקור מלא · 6 מקורות

אותו אירוע, כפי שכל חדר חדשות דיווח עליו בנפרד. פתחו כמה כדי להשוות במה כל אחד מדגיש ומה הוא משמיט.

GlobesUnrated · עבריתאוג׳ 27, 2026

FDA Approves Revolutionary Pancreatic Cancer Drug Boosting Revolution Medicines' Valuation

Arutz ShevaRight · עבריתאוג׳ 27, 2026

FDA Approves Breakthrough Drug for Advanced Pancreatic Cancer Extending Survival

WallaCenter · עבריתאוג׳ 27, 2026

FDA Approves Israeli-Developed Drug Nearly Doubling Survival in Advanced Pancreatic Cancer

Behadrei HaredimRight · עבריתאוג׳ 26, 2026

FDA Approves New Drug Doubling Survival in Metastatic Pancreatic Cancer Amid High Costs

YnetCenter · עבריתאוג׳ 26, 2026

FDA Approves Breakthrough Oral Drug Drexonersib for Metastatic Pancreatic Cancer

YnetCenter · עבריתאוג׳ 26, 2026

FDA Approves Breakthrough Oral Drug for Metastatic Pancreatic Cancer, Offering New Hope

Now 14Right · עבריתאוג׳ 26, 2026

FDA Approves New Targeted Therapy Doubling Survival in Metastatic Pancreatic Cancer

סיפורים קשורים

New Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdlesאוג׳ 30, 2026FDA Approves Revtorpyk to Cut Advanced Breast Cancer Progression Risk by 76%יולי 15, 2026Ichilov Launches World-First Clinical Trial for Innovative Pancreatic Cancer Treatmentיולי 30, 2026Cancer Vaccine Shows Promise, Leaving One Patient Disease-Free for More Than Six Yearsיוני 11, 2026Israeli Biotech Silaxion Reveals SIL204 May Boost Immune System to Target Tumorsאוג׳ 5, 2026Moderna and MSD Achieve Breakthrough With Personalized mRNA Cancer Vaccine in Phase 3 Trialאוג׳ 19, 2026